Cargando…

Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy

PURPOSE: To investigate the prognostic value of 17 platelet-based prognostic scores in patients with malignant hepatic tumors after TACE therapy. METHODS: In total, 92 patients were divided into death group and survival group according to long-term follow-up results. The AUC was calculated to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Qian Cheng, Hu, Chen Liang, Wang, Yan Yan, Zhou, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756010/
https://www.ncbi.nlm.nih.gov/pubmed/31531530
http://dx.doi.org/10.1590/s0102-865020190070000010
_version_ 1783453332414660608
author Du, Qian Cheng
Hu, Chen Liang
Wang, Yan Yan
Zhou, Ying
author_facet Du, Qian Cheng
Hu, Chen Liang
Wang, Yan Yan
Zhou, Ying
author_sort Du, Qian Cheng
collection PubMed
description PURPOSE: To investigate the prognostic value of 17 platelet-based prognostic scores in patients with malignant hepatic tumors after TACE therapy. METHODS: In total, 92 patients were divided into death group and survival group according to long-term follow-up results. The AUC was calculated to determine the optimal cut-off values for predicting prognosis. To determine better prognostic models, platelet-based models were analyzed separately after being showed as binary according to cut-off values. Cumulative survival rates of malignant hepatic tumors were calculated using Kaplan-Meier curves and differences were analyzed by the log-rank test. Univariate and multivariate analyses were performed to identify platelet-based prognostic scores associated with overall survival. RESULTS: Univariate analysis showed that APGA, APRI, FIB-4, FibroQ, GUCI, King's score, Lok index, PAPAS, cirrhosis, number of tumors, vascular cancer embolus, AFP, ALP and APTT were significantly related to prognosis. A multivariate analysis showed that the APGA, number of tumors, ALP and APTT were independently associated with overall survival. CONCLUSION: This study showed that the APGA, a platelet-based prognostic score, was an independent marker of prognosis in patients with malignant hepatic tumors after TACE and was superior to the other platelet-based prognostic scores in terms of prognostic ability.
format Online
Article
Text
id pubmed-6756010
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
record_format MEDLINE/PubMed
spelling pubmed-67560102019-09-27 Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy Du, Qian Cheng Hu, Chen Liang Wang, Yan Yan Zhou, Ying Acta Cir Bras Original Article PURPOSE: To investigate the prognostic value of 17 platelet-based prognostic scores in patients with malignant hepatic tumors after TACE therapy. METHODS: In total, 92 patients were divided into death group and survival group according to long-term follow-up results. The AUC was calculated to determine the optimal cut-off values for predicting prognosis. To determine better prognostic models, platelet-based models were analyzed separately after being showed as binary according to cut-off values. Cumulative survival rates of malignant hepatic tumors were calculated using Kaplan-Meier curves and differences were analyzed by the log-rank test. Univariate and multivariate analyses were performed to identify platelet-based prognostic scores associated with overall survival. RESULTS: Univariate analysis showed that APGA, APRI, FIB-4, FibroQ, GUCI, King's score, Lok index, PAPAS, cirrhosis, number of tumors, vascular cancer embolus, AFP, ALP and APTT were significantly related to prognosis. A multivariate analysis showed that the APGA, number of tumors, ALP and APTT were independently associated with overall survival. CONCLUSION: This study showed that the APGA, a platelet-based prognostic score, was an independent marker of prognosis in patients with malignant hepatic tumors after TACE and was superior to the other platelet-based prognostic scores in terms of prognostic ability. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019-09-16 /pmc/articles/PMC6756010/ /pubmed/31531530 http://dx.doi.org/10.1590/s0102-865020190070000010 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Du, Qian Cheng
Hu, Chen Liang
Wang, Yan Yan
Zhou, Ying
Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title_full Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title_fullStr Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title_full_unstemmed Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title_short Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy
title_sort comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after tace therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756010/
https://www.ncbi.nlm.nih.gov/pubmed/31531530
http://dx.doi.org/10.1590/s0102-865020190070000010
work_keys_str_mv AT duqiancheng comparisonoftheprognosticvalueofplateletbasedprognosticmodelsinpatientswithmalignanthepatictumorsaftertacetherapy
AT huchenliang comparisonoftheprognosticvalueofplateletbasedprognosticmodelsinpatientswithmalignanthepatictumorsaftertacetherapy
AT wangyanyan comparisonoftheprognosticvalueofplateletbasedprognosticmodelsinpatientswithmalignanthepatictumorsaftertacetherapy
AT zhouying comparisonoftheprognosticvalueofplateletbasedprognosticmodelsinpatientswithmalignanthepatictumorsaftertacetherapy